Mark H. O’Hara

Hospital of the University of Pennsylvania

Also affiliated with University of Pennsylvania

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Challenges and Opportunities for Pancreatic Cancer Immunotherapy”.

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Cancer Cell(2020)10.1016/j.ccell.2020.08.004

N/A

0.971DataRank · unranked

645 citations

Robert H. Vonderheide, Mark H. O’Hara, Adham S. Bear

An NK-like CAR T cell transition in CAR T cell dysfunction

Cell(2021)10.1016/j.cell.2021.11.016

N/A

0.902DataRank · unranked

409 citations

M. Ángela Aznar, Shunichiro Kuramitsu, Parisa Samareh, Sangya Agarwal, Greg Donahue +25 more

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1467

N/A

0.873DataRank · unranked

24 citations

Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood +9 more

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors

Journal of Clinical Investigation(2024)10.1172/jci175790

N/A

0.794DataRank · unranked

28 citations

Rebecca B. Nadler, Mark H. O’Hara, Kelsey Stanton, Chong Xu, Robert Saporito +14 more

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1047

N/A

0.784DataRank · unranked

185 citations

Courtney B. Betts, Rosemarie Mick, Shamilene Sivagnanam, David L. Bajor, Daniel A. Laheru +24 more

Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer

Molecular Therapy(2020)10.1016/j.ymthe.2020.07.017

N/A

0.606DataRank · unranked

56 citations

Alexander C. Jordan, Evan Tooker, Simon F. Lacey, Renee B. Chang, Yan Li +11 more

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae114

N/A

0.443DataRank · unranked

10 citations

Paul J. Catalano, Michelle Weitz, Edith Mitchell, Deirdre Jill Cohen, Peter J O’Dwyer +9 more

Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102301

N/A

0.429DataRank · unranked

14 citations

Charly R. Good, Julie S. Barber-Rotenberg, Sangya Agarwal, Wesley V. Wilson, Alex Watts +27 more

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

Nature Communications(2024)10.1038/s41467-024-49915-5

N/A

0.396DataRank · unranked

13 citations

Lee McDaniel, Changgee Chang, Qi Long, Shannon M. Pfeiffer, Jaclyn P. Lyman +37 more

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0036

N/A

0.330DataRank · unranked

8 citations

Opeyemi A. Jegede, Mark A. Dickson, Angela DeMichele, Richard Piekarz, Robert J. Gray +15 more

Final results of a phase I “RadVax” trial of hypofractionated radiation combined with pembrolizumab in patients with metastatic solid tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2576

N/A

0.241DataRank · unranked

4 citations

Rosemarie Mick, Alexander C. Huang, Nicholas Han, Michael D. Farwell, Tara C. Mitchell +11 more

A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4131

N/A

0.165DataRank · unranked

2 citations

Mark H. O’Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Natallia Izgur +4 more

Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4122

N/A

0.104DataRank · unranked

1 citations

Aseel Abdalla, Neha Bhagwat, Taylor A. Black, Zhuoyang Wang, Stephanie S. Yee +15 more

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Nature Communications(2021)10.1038/s41467-021-24562-2

N/A

0DataRank · unranked

112 citations

Tatiana Blanchard, Joseph Cesare, Michael Ford, Lee P. Richman, Chong Xu +14 more

592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0592

N/A

0DataRank · unranked

2 citations

Richard D. Carvajal, Diwakar Davar, Eduardo Castañón, Paolo A. Ascierto, Emiliano Calvo +16 more

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0519

N/A

0DataRank · unranked

14 citations

Mark H. O’Hara, Ben Z. Stanger, Kim A. Reiss, Minh T. Than

THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma

Oncotarget(2021)10.18632/oncotarget.28099

N/A

0DataRank · unranked

5 citations

Jacob E. Till, Shirsa Udgata, Naomi Takenaka, Stephanie S. Yee, Michael J. LaRiviere +8 more